Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future (Q37514748)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 March 2013

Language	Label	Description	Also known as
English	Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future	scientific article published on 07 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

6 references

23 March 2019

20 June 2019

12 October 2019

2 November 2019

4 October 2020

28 November 2023

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

12 October 2019

1 reference

2 November 2019

cell-derived microparticles

1 reference

4 October 2020

meningococcal vaccine

1 reference

24 January 2021

2

object named as

Philipp Oster

1 reference

Europe PubMed Central

20 August 2017

Jane M O'Hallahan

9

object named as

Jane O'Hallahan

1 reference

Europe PubMed Central

20 August 2017

Ingeborg S Aaberge

6

object named as

Ingeborg S Aaberge

1 reference

Europe PubMed Central

20 August 2017

Einar Rosenqvist

10

object named as

Einar Rosenqvist

1 reference

Europe PubMed Central

20 August 2017

author name string

Johan Holst

1

1 reference

Europe PubMed Central

20 August 2017

Richard Arnold

3

1 reference

Europe PubMed Central

20 August 2017

Michael V Tatley

4

1 reference

Europe PubMed Central

20 August 2017

Lisbeth M Næss

5

1 reference

Europe PubMed Central

20 August 2017

Yvonne Galloway

7

1 reference

Europe PubMed Central

20 August 2017

Anne McNicholas

8

1 reference

Europe PubMed Central

20 August 2017

Steven Black

11

1 reference

Europe PubMed Central

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

7 March 2013

1 reference

Europe PubMed Central

20 August 2017

1 June 2013

7 references

23 March 2019

20 June 2019

12 October 2019

2 November 2019

4 October 2020

24 January 2021

28 November 2023

Human Vaccines & Immunotherapeutics

8 references

Europe PubMed Central

20 August 2017

23 March 2019

20 June 2019

12 October 2019

2 November 2019

4 October 2020

24 January 2021

28 November 2023

9

1 reference

Europe PubMed Central

20 August 2017

6

1 reference

Europe PubMed Central

20 August 2017

1241-1253

1 reference

Europe PubMed Central

20 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

7 references

Europe PubMed Central

23 March 2019

Europe PubMed Central

20 June 2019

Europe PubMed Central

12 October 2019

Europe PubMed Central

2 November 2019

Europe PubMed Central

4 October 2020

Europe PubMed Central

24 January 2021

Europe PubMed Central

28 November 2023

Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Meningococcal glycoconjugate vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Advances in the development of vaccines against Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Review of meningococcal group B vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Serogroup B meningococcal vaccines-an unfinished story

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Chapter 28: a history of bacterial meningitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Challenges and progress in the development of a serogroup B meningococcal vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

MeNZB vaccine and epidemic control: when do you stop vaccinating?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Conquering the meningococcus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Clinical practice. Prevention of meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

A universal vaccine for serogroup B meningococcus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Serologic correlates of protection for evaluating the response to meningococcal vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Case fatality rates for meningococcal disease in an English population, 1963-98: database study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Development of natural immunity to Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

23 August 2017

Considerations for controlling invasive meningococcal disease in high income countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

6 September 2017

Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

6 September 2017

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

6 September 2017

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

6 September 2017

Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

6 September 2017

Human bactericidal antibody response to meningococcal outer membrane protein vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

14 September 2017

Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

14 September 2017

The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

14 September 2017

Global epidemiology of meningococcal disease and vaccine efficacy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

14 September 2017

Five structural classes of major outer membrane proteins in Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

14 September 2017

The Outbreak of Cerebrospinal Fever at Salisbury in 1914-15.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

28 September 2017

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

25 June 2018

Immunologic response of man to group B meningococcal polysaccharide vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

25 June 2018

Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

25 June 2018

Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Outer membrane protein vesicle vaccines for meningococcal disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

The strategy to control New Zealand's epidemic of group B meningococcal disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Trend in incidence and case fatality of meningococcal disease over 16 years in Northern Denmark.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3901813

2 September 2018

Phase II meningococcal B vesicle vaccine trial in New Zealand infants

1 reference

https://api.crossref.org/works/10.4161%2FHV.24129

21 January 2018

New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16???24 Months

1 reference

https://api.crossref.org/works/10.4161%2FHV.24129

21 January 2018

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serogroup B meningococcal disease: new outbreaks, new strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of bronchiolitis hospitalisation following administration of a group B meningococcal vaccine in New Zealand

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uncloaking the meningococcus: dynamics of carriage and disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surveillance of vaccine breakthrough cases following MeNZB vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serotype determinant protein of Neisseria Meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemic

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Henoch-Schönlein purpura and meningococcal B vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/HV.24129

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37514748&oldid=2019528946"